FHTX Q1 2022 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+1270.6% YoY

Gross Profit

-$21M-525.2% margin

Operating Income

-$28M-709.3% margin

Net Income

-$27M-686.6% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

+449.8%

Cash Flow

Operating Cash Flow

$272M

Free Cash Flow

$271M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$488M

Total Liabilities

$416M

Stockholders' Equity

$72M

Cash & Equivalents

$214M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$286,000	+1270.6%
Gross Profit	-$21M	-$18M	-11.6%
Operating Income	-$28M	-$23M	-20.2%
Net Income	-$27M	-$23M	-17.1%